Electra JV “obviously in the right place” after sampling

|

Published 05-JUL-2016 15:27 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The head of the Lithium Australia (ASX:LIT) Alix Resources (CN:AIX) joint venture says it is “obviously in the right location” after latest round of drilling at its Electra lithium project in Mexico.

Joint venture partner LIT told the Australian market late last week that sampling at the Senora Project in Mexico came back with lithium values of up to 246 parts per million lithium.

It said that this confirmed a target sedimentary assemblage with the potential of having lithium-bearing, clay-rich horizons.

Alix president Mike England went one step further, saying the results confirmed the project bore striking similarities to the Bacanora/REM project right next door.

“These recent anomalous and enriched lithium values...bear similarities to Bacanora/REM’s early stage findings at Buenavista,” England said.

The Buenavista deposit is within the Sonora Porject, a joint venture between Bacanora and REM which was at the centre of a lithium hydroxide supply deal inked with auto giant Tesla late last year.

The Electra lithium project in Mexico

The Electra lithium project in Mexico

The LIT/AIX joint venture gathered 42 samples from claystones, sandstone and siltstones from its target sedimentary sequence – which bore an average lithium value of 167ppm.

The sampling program has effectively firmed up two target areas at the project, one measuring 1100m by 250-400m, and the other 400m by 150m.

Both parties will now get to work on another round of sampling at the project, followed by a series of shallow drill holes as part of a drilling campaign.

These drill holes are not guaranteed to hit lithium mineralisation.

England, however, said the first round of sampling had a huge validating effect.

“We are obviously in the right location and the mineralisation to date found on the property is very promising to our exploration team,” he said.

Back in May LIT confirmed that it had taken the first 25% interest as part of an overall program which could earn LIT a 65% stake in the project.

About LIT and Sileach

LIT will be hoping to apply its ‘Sileach’ processing process to the project – proving that the process is good for processing clays as well as hard rock sources.

The Sileach process is a way of processing lower-grade silicate deposits normally considered sub-economic.

The Sileach process involves grounding the test ore, digesting it in sulphuric acid, removing impurities and then extracting the lithium carbonate.

If LIT is able to prove up the technology, then it could open up a raft of resource which were previously considered too poor to mine.

tags

LITHIUM


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X